CN Patent

CN100500151C — 一种水溶性药物舌下给药制剂

Assigned to Aventis Pharma Hainan Co ltd · Expires 2009-06-17 · 17y expired

What this patent protects

本发明提供了一种水溶性药物舌下溶解的片剂处方组成，通过调节渗透剂的合适组方比例，实现药物在舌下10～20分钟内缓慢溶化，并使药物的体内外溶化时间与片剂硬度变化无关。该片剂的水溶性有效成分，可以是盐酸阿扑吗啡、盐酸丁丙诺啡、盐酸二氢埃托啡、氯雷他定；优选盐酸阿扑吗啡。

USPTO Abstract

本发明提供了一种水溶性药物舌下溶解的片剂处方组成，通过调节渗透剂的合适组方比例，实现药物在舌下10～20分钟内缓慢溶化，并使药物的体内外溶化时间与片剂硬度变化无关。该片剂的水溶性有效成分，可以是盐酸阿扑吗啡、盐酸丁丙诺啡、盐酸二氢埃托啡、氯雷他定；优选盐酸阿扑吗啡。

Drugs covered by this patent

apomorphine-hydrochloride (APOMORPHINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN100500151C
Jurisdiction: CN
Classification: —
Expires: 2009-06-17
Drug substance claim: No
Drug product claim: No
Assignee: Aventis Pharma Hainan Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.